Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 791

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 791
---
 to support the joint development of an innovative treatment in the field of diabetes by the Company and iTolerance, with a total budget of USD $2 million for a period of 30 months (hereinafter, the “Grant period”). The total grants received in 2024 from the BIRD Foundation are USD $250 thousand. As of December 31, 2024, the Company has an outstanding balance of USD $42 thousand in respect of deferred receivables from the BIRD Foundation. G.On February 14, 2024, the Company entered into a non -bindingmemorandum of understanding (hereinafter, the “MOU”) for a merger with IMC Corp (Nasdaq: “IMCC”), a company whose shares are traded in the United States on the Nasdaq Stock Market and in Canada on the Canadian Securities Exchange (CNSX) (hereinafter, the “IMC”). IMC is incorporated under the laws of Canada. On May 27, 2024, negotiations between the parties to sign a final agreement were terminated, inter alia, in light of regulatory changes in IMC’s field of activity in the American market and in the German market, which are not related to the Company. In accordance with the separation agreement signed between the parties on that date, the loan that the Company provided to an IMC subsidiary within the framework of the aforementioned Annex G-32

KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 17: — Contingent liabilities and COMMITMENTS (cont.) MOU, amounting to USD $300 thousand, will be repaid to the Company plus annual interest at a rate of 9% for the outstanding period, in 3 equal installments, the last of which was to be transferred to the Company no later than July 31, 2024 and to which the interest accrued during the period would be added. The balance of the loan was recorded in accounts receivable. As of June 30, 2024, the balance of the loan was USD $188 thousand and financing income was recorded in respect thereof amounting to USD $8 thousand. As of the date of these financial statements, the Company has collected all payments in accordance with the separation agreement, and as of December 31, 2024, there is no balance outstanding. H.Agreement with Pluri Inc. On July 17, 2024, the Company entered into a collaboration agreement with Pluri Inc. (N